This Core Center of Excellence in Hematology (CCEH) is designed to overcome feasibility issues that limit the ability of individual investigators to apply state-of-the-art methods to isolate, characterize, manipulate and functionally analyze hematopoietic cells. This is achieved through services provided by the five biomedical research cores: B, large scale cell processing;C, clonal analysis;D,vector production;E. xenografting;and F, canine resources. The Administrative Core (Core A) provides managerial, scientific, and budgetary oversight for these core activities. In addition Core A is responsible for administrating the Pilot and Feasibility (P&F) studies program and the Enrichment Program. These two programs are supported by program income derived from charge back fees levied for core services. Management of program income is also under the purview of Core A. The Enrichment Program, under the direction of the Administrative Core, serves the hematology research community by sponsoring 3-6 outside speakers per year to present at the well-established Clinical Research Division Monday noon lecture series. This lecture series also provides CCEH members with an opportunity to formally present their research, which Is a requirement for appointments and promotions. Lectures are held every Monday at the FHCRC and usually attract between 50-75 people. Lectures are also made available through a live feed to the UW, Children's Hospital, Seattle Cancer Care Alliance, Seattle VA, University of British Columbia, and University of Victoria. The live feed allows audience participation at the remote sites. Faculty members attending these lectures will receive CME credits. In addition to the sponsored speaker program, the CCEH will co-sponsor a workshop on circulating microRNAs and DNAs, and their potential role In mediating cell to cell interactions. This workshop will be cosponsored by the Cancer Center Support Grant (CCSG, CA 15704) and is described in more detail under 'New Initiatives".

National Institute of Health (NIH)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Busch, S E; Moser, R D; Gurley, K E et al. (2014) ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma. Oncogene 33:2665-73
Watts, Korashon L; Beard, Brian C; Wood, Brent L et al. (2014) No evidence of clonal dominance after transplant of HOXB4-expanded cord blood cells in a nonhuman primate model. Exp Hematol 42:497-504
Klippel, Z K; Chou, J; Towlerton, A M et al. (2014) Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Ther 21:337-42
Wurm, Melanie; Kowalski, John; Heckl, Dirk et al. (2014) Ectopic expression of HOXC6 blocks myeloid differentiation and predisposes to malignant transformation. Exp Hematol 42:114-25.e4
Adair, Jennifer E; Johnston, Sandra K; Mrugala, Maciej M et al. (2014) Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J Clin Invest 124:4082-92
Iwata, Mineo; Sandstrom, Richard S; Delrow, Jeffrey J et al. (2014) Functionally and phenotypically distinct subpopulations of marrow stromal cells are fibroblast in origin and induce different fates in peripheral blood monocytes. Stem Cells Dev 23:729-40
Green, Damian J; Orgun, Nural N; Jones, Jon C et al. (2014) A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. Cancer Res 74:1179-89
Burtner, Christopher R; Beard, Brian C; Kennedy, Douglas R et al. (2014) Intravenous injection of a foamy virus vector to correct canine SCID-X1. Blood 123:3578-84
Bleakley, Marie; Heimfeld, Shelly; Jones, Lori A et al. (2014) Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant 20:705-16
Shu, Z; Heimfeld, S; Gao, D (2014) Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion. Bone Marrow Transplant 49:469-76

Showing the most recent 10 out of 175 publications